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Background: As more countries worldwide develop national viral hepatitis strategies, it is important to ask whether
context-specific factors affect their decision-making. This study aimed to determine whether country-level socioeconomic
factors are associated with viral hepatitis programmes and policy responses across WHO Member States (MS).
Methods: WHO MS focal points completed a questionnaire on national viral hepatitis policies. This secondary analysis of
data reported in the 2013 Global Policy Report on the Prevention and Control of Viral Hepatitis in WHO Member States used
logistic regression to examine associations between four survey questions and four socioeconomic factors:
country income level, Human Development Index (HDI), health expenditure and physician density.
Results: This analysis included 119 MS. MS were more likely to have routine viral hepatitis surveillance and to
have a national strategy and/or policy/guidelines for preventing infection in healthcare settings if they were in
the higher binary categories for income level, HDI, health expenditure and physician density. In multivariable
analyses, the only significant finding was a positive association between having routine surveillance and being
in the higher binary HDI category (adjusted odds ratio 26; 95% confidence interval 2.0–340).
Conclusion: Countries with differing socioeconomic status indicators did not appear to differ greatly regarding the
existence of key national policies and programmes. A more nuanced understanding of the multifaceted interactions of
socioeconomic factors, health policy, service delivery and health outcomes is needed to support country-level efforts to
eliminate viral hepatitis.
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Hepatitis B virus (HBV) and hepatitis C virus (HCV)
combined are the seventh-leading cause of death globally,
with most deaths resulting from HBV- and HCV-associated
cirrhosis and liver cancer [1]. There are thought to be
approximately 250 million people worldwide living with
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approximately 130–150 million [3]. Despite regional
variations, viral hepatitis is widely regarded as a global
public health problem. In 2013, low-income and lower-
middle-income countries accounted for 42% of viral
hepatitis deaths, and upper-middle-income and high-
income countries, 58% [1].
There are reliable interventions for preventing and man-
aging both infections, including a safe and effective hepatitis
B vaccine [4] as well as antiviral treatment regimens that can
cure more than 90% of cases of hepatitis C [3]. Although
HBV cannot be cured, the damaging consequences of thele is distributed under the terms of the Creative Commons Attribution 4.0
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tions [4]. In light of the current state of knowledge, it is
theoretically possible to eliminate both diseases from all
populations worldwide. However, the current global disease
burden suggests that many countries are far from achieving
sufficient uptake of strategies proven to work well.
The inclusion in the Sustainable Development Goals of a
target to “combat hepatitis” [5] reflects a growing consensus
that this group of diseases, particularly HBV and HCV,
must be addressed decisively at the global and national
policy levels. The World Health Assembly’s 2010 and 2014
viral hepatitis resolutions [6, 7] have given direction to the
policy response, in part by informing how the World
Health Organization (WHO) works with Member States
(MS) on viral hepatitis issues. More recently, MS endorsed
WHO’s goal of eliminating viral hepatitis as a public health
threat with their approval of the Global Health Sector
Strategy on Viral Hepatitis, 2016–2021 [3].
As of this writing, the only published assessment of
national policy responses to viral hepatitis across multiple
countries and regions is the 2013 Global Policy Report on
the Prevention and Control of Viral Hepatitis in WHO
Member States [8]. Survey findings presented in the report
indicate that at the time the data were collected, WHO
MS diverged from each other in many ways regarding
how they addressed viral hepatitis. In the current policy
environment, when increasingly more countries world-
wide are developing their first national viral hepatitis strat-
egies or considering how to strengthen existing strategies,
it is important to try to identify context-specific factors
that may affect their decision-making.
Implementing the policy measures advocated by the
World Health Organization in the Global Health Sector
Strategy and in its guidance on the development of national
viral hepatitis plans [9] requires multiple types of resources
such as financial resources, technical expertise and an exten-
sive health system infrastructure. Socioeconomic indicators
relating to country income level, Human Development
Index (HDI) score, health expenditure and physician
density have been investigated as possible predictors of
maternal mortality and the incidence and prevalence of
cancer, infectious diseases and injuries, among other
health outcomes [10–14]; this raises the question of
whether such proxy measures of how well-resourced a
country is can also be used to predict a strong or weak
policy response to viral hepatitis. The following study
sought to identify associations between country-level
socioeconomic indicators and viral hepatitis programme
and policy responses across WHO MS.
Methods
Data sources
The methodology for the survey that provided the basis
of the 2013 Global Policy Report has been describedelsewhere [8]. In short, a survey with 43 policy-related
questions was sent to the government focal point for
viral hepatitis in each of the 194 MS of the World Health
Organization. Data collection took place from July 2012 to
February 2013.
Four survey questions were selected from the 2013
Global Policy Report as measures of Member States’
commitment to combatting viral hepatitis. These served
as dependent variables for analyses performed in this
study. One question asked if countries have a written na-
tional strategy or plan that focuses exclusively or primar-
ily on the prevention and control of viral hepatitis. The
second question asked if there is routine surveillance for
viral hepatitis. The third question asked if governments
had funded World Hepatitis Day or any public viral hepa-
titis awareness campaign since January 2011. The fourth
question asked if there is a national strategy and/or policy/
guidelines for preventing hepatitis B and hepatitis C infec-
tion in healthcare settings.
A follow-up question to the fourth question asked if
health workers were vaccinated against hepatitis B prior
to starting work that might put them at risk of exposure
to blood.
The four socioeconomic indicators chosen to serve as
independent variables in the current study came from
multiple sources. Income level data were drawn from the
World Bank country classifications for 2013, which were
defined as follows: low income, ≤$1035; lower middle in-
come, $1036–$4085; upper middle income, $4086–$12,615;
and high income, ≥$12,616 [15]. HDI data for 2013 were
sourced from the United Nations Development Programme
(UNDP) database, which provides a proxy index of develop-
ment using the geometric mean of three measures: life
expectancy at birth, mean years over expected years of
schooling, and gross national income (GNI) per capita in
US dollars based on purchasing power parity [16]. Health
expenditure data for 2013 were obtained from the WHO
global health expenditure database, which reflects per capita
total expenditure on health in US dollars at the average
exchange rate [17]. Physician density, as indicated by the
number of medical doctors per 1000 people, was obtained
from the WHO global health workforce statistics database
[18]. Data were for 2013 or the most recent year prior to
that for which information was available.
Data analysis
WHO MS that submitted surveys for the 2013 Global
Policy Report were included in the current study if they
had data available for all four independent variables
considered in this study. Each Member State received a
binary designation of “low” or “high” for each independent
variable as well as a quadripartite designation of “low”,
“lower middle”, “upper middle” or “high”. The categories
for country income level were defined in accordance with
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lower two World Bank groupings constituting the “low”
group and the higher two constituting the “high” group
for the binary classification. The categories for the
other three independent variables were determined by
calculating quartiles for each dataset, i.e., for HDI scores,
health expenditure and physician density. In each case,
quartiles were determined using values from the full dataset
rather than from only the countries included in the
study analysis.
Proportions were calculated using the number of respond-
ing MS as denominators. Proportions were compared using
the Fisher’s exact test. The Mann-Whitney test was used
with quadripartite groupings. Univariate logistic regression
was used to calculate odds ratios (OR) and 95% confidence
intervals (CI) for the four binary independent variables in re-
lation to each dependent variable. All possible combinations
of independent variables were used in logistic regressions
with each dependent variable in order to test whether any
associations were affected by independent variables influen-
cing each other (confounding, effect modification and collin-
earity). Univariate logistic regression with quadripartite
independent variables was used to investigate stepwise
relationships for each of the dependent variables. The
lowest category was the reference group in each case.
Binary independent variables were selected for the
multivariable models based on univariate results. Final
models for each of the dependent variables were se-
lected based on stepwise forward multivariable logistic
regression using the Akaike information criterion and
likelihood ratio tests.
All analyses were two-tailed, with a significance level
of 0.05. All analyses were carried out using R statistical soft-
ware version 3.1.2 (Foundation for Statistical Computing,
Vienna, Austria).Results
Respondents
The survey that provided the basis for the 2013
Global Policy Report was completed by 126 of 194
WHO Member States (65%). Data for one or more
of the independent variables considered in this study
were not available for seven MS (Democratic People’s
Republic of Korea, Russian Federation, San Marino,
Slovenia, Somalia, South Sudan and Zimbabwe). Thus
119 MS – 61% of all MS – were included in the
analysis.
The response rate was higher for MS with HDI scores
in the above-median category in comparison to below-
median countries (p = 0.001). Likewise, MS with above-
median physician density had higher response rates than
those with below-median physician density (p < 0.001)
(data not shown).Descriptive analysis
Among the 119 MS included in the analysis, 44 (37%)
reported having a written national viral hepatitis strategy
or plan. Ninety-nine (83%) reported having routine sur-
veillance for viral hepatitis; 53 (45%) reported funding
viral hepatitis awareness campaigns; 84 (71%) reported
having a strategy and/or policy/guidelines for preventing
hepatitis B and hepatitis C infection in healthcare set-
tings; and 77 (79%) reported that health workers were
vaccinated against hepatitis B prior to starting work that
might put them at risk of exposure to blood.
Significantly higher proportions of Member States re-
ported having routine surveillance, having a healthcare
setting prevention strategy and/or policy/guidelines, and
having health worker vaccination in the higher binary
categories for all four socioeconomic indicators. The pro-
portions of affirmative survey answers for the same three
dependent variables also increased with each increase in
quartile categories for all four socioeconomic indicators.
Mann-Whitney tests showed statistically significant increas-
ing trends in each case (Table 1). For the survey question
about routine viral hepatitis surveillance, 100% of respon-
dents in the highest quartiles for all four socioeconomic
indicators reported having routine surveillance.
Univariate logistic regression
Results of univariate logistic regression mirrored those
found in descriptive analyses. MS were more likely to
report having routine viral hepatitis surveillance if they
were in the higher binary categories for income level
(OR 12; 95% CI 3.9–56), HDI (OR 44; 95% CI 8.4–
800), health expenditure (OR 15; 95% CI 4.0–98) and
physician density (OR 8.8; 95% CI 2.9–33). Likewise,
they were more likely to report having a national strat-
egy and/or policy/guidelines for preventing infection in
healthcare settings if they were in the higher binary
categories for income level (OR 8.1; 95% CI 3.4–21),
HDI (OR 6.3; 95% CI 2.7–16), health expenditure (OR
5.5; 95% CI 2.3–14) and physician density (OR 4.7;
95% CI 2.1–11).
When successively higher quartiles of the four socioeco-
nomic indicators were compared to the lowest quartiles,
MS were found to have increasingly higher odds of an-
swering affirmatively to the routine surveillance question
and to the healthcare setting prevention question as their
quartile rankings increased (Table 2). Odds ratios could
not be computed for the highest quartiles for any of the
socioeconomic indicators in relation to the routine sur-
veillance question because 100% of the highest-quartile
MS in all four cases had routine surveillance.
Multivariable logistic regression
In fully adjusted multivariable models, socioeconomic indi-
cator variables continued to not have significant associations
Table 1 Frequency and proportion of respondents reporting policies or programme activities by socioeconomic indicator quartiles
Income level groups n (% group)
Low
N = 14
Lower middle
N = 34
Upper middle
N = 33
High
N = 38
p-valueǂ
National strategy or plan 4 (29) 13 (38) 13 (39) 14 (37) <0.001
Routine surveillance 6 (43) 25 (74) 30 (91) 38 (100) <0.001
Awareness campaign 3 (21) 18 (53) 17 (52) 15 (40) <0.001
Prevention in healthcare settings 5 (36) 17 (50) 29 (88) 33 (87) <0.001
Health worker vaccination 2 (25) 15 (60) 27 (87) 33 (97) <0.001
Human Development Index groups n (% group)
Low
N = 21
Lower middle
N = 28
Upper middle
N = 33
High
N = 37
p-valueǂ
National strategy or plan 4 (19) 14 (50) 12 (36) 14 (38) <0.001
Routine surveillance 8 (38) 22 (79) 32 (97) 37 (100) <0.001
Awareness campaign 8 (38) 12 (43) 16 (49) 17 (46) <0.001
Prevention in healthcare settings 7 (33) 17 (61) 26 (79) 34 (92) <0.001
Health worker vaccination 2 (20) 16 (64) 25 (89) 34 (97) <0.001
Health expenditure groups n (% group)
Low
N = 25
Lower middle
N = 30
Upper middle
N = 28
High
N = 36
p-valueǂ
National strategy or plan 6 (24) 14 (47) 10 (36) 14 (39) <0.001
Routine surveillance 12 (48) 25 (83) 26 (93) 36 (100) <0.001
Awareness campaign 7 (28) 18 (60) 13 (46) 15 (42) <0.001
Prevention in healthcare settings 7 (28) 22 (73) 24 (86) 31 (86) <0.001
Health worker vaccination 6 (40) 16 (64) 24 (92) 31 (97) <0.001
Physician density groups n (% group)
Low
N = 19
Lower middle
N = 28
Upper middle
N = 34
High
N = 38
p-valueǂ
National strategy or plan 4 (21) 11 (39) 16 (47) 13 (34) <0.001
Routine surveillance 7 (37) 24 (86) 30 (88) 38 (100) <0.001
Awareness campaign 6 (32) 13 (46) 13 (38) 21 (55) <0.001
Prevention in healthcare settings 5 (26) 19 (68) 28 (82) 32 (84) <0.001
Health worker vaccination 3 (27) 18 (75) 25 (83) 31 (94) <0.001
ǂMann-Whitney test
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funding of awareness campaigns. Socioeconomic associa-
tions observed for the question about prevention in health-
care settings were no longer significant. In the final (fully
adjusted) model, MS in the higher binary HDI category for
all of the socioeconomic indicators were more likely than
MS in the lower binary category to report having routine
surveillance (adjusted OR 26; 95% CI 2.0–340) (Table 3).
Discussion
This study adds to the growing body of literature on
health governance in a global setting [20]. Although the
association of individual wealth and health outcomes has
been extensively researched [21], our study appears to
be unique in that it addresses the potential influencethat national socioeconomic indicators have on hepatitis
governance and policy. Such a line of inquiry seems im-
portant to introduce into the health policy discourse in
light of the resource constraints that hobble many aspects
of health system functioning in poorer countries. That is,
the starting point for our study was the hypothesis that
such constraints may inhibit health policy-making. In
regard to national responses to viral hepatitis, this study
has yielded the intriguing finding that countries with
higher and lower measures of socioeconomic status (SES)
do not appear to differ greatly regarding their likelihood
of reporting the existence of some national policies and
programmes. The overall state of the policy response to
viral hepatitis during the time period captured in the 2013
Global Policy Report suggests that urgent action may be
Table 2 Univariate logistic regression producing crude odds
ratios for associations between two survey questions and four
socioeconomic indicators, by quartile
Nexposed (%) Nunexposed (%) OR 95% CI
Routine surveillance
Income level groups
Low 6 (43) 8 (57) Ref. -
Lower middle 25 (74) 9 (26) 3.7 (1.0–14)
Upper middle 30 (91) 3 (9) 13 (3.0–77)
High 38 (100) 0 (0) ∞ ∞
Human Development Index groups
Low 8 (38) 13 (62) Ref. -
Lower middle 22 (79) 6 (21) 6.0 (1.8–23)
Upper middle 32 (97) 1 (3) 52 (8.5–1020)
High 37 (100) 0 (0) ∞ ∞
Health expenditure groups
Low 12 (48) 13 (52) Ref. -
Lower middle 25 (83) 5 (17) 5.4 (1.7–20)
Upper middle 26 (93) 2 (7) 14 (3.3–100)
High 36 (100) 0 (0) ∞ ∞
Physician density groups
Low 7 (37) 12 (63) Ref. -
Lower middle 24 (86) 4 (14) 10 (2.7–47)
Upper middle 30 (88) 4 (12) 13 (3.4–59)
High 38 (100) 0 (0) ∞ ∞
Prevention in healthcare settings
Income level groups
Low 5 (36) 9 (64) Ref. -
Lower middle 17 (50) 17 (50) 1.8 (0.5–7.0)
Upper middle 29 (88) 4 (12) 13 (3.1–67)
High 33 (87) 5 (13) 12 (3.0–55)
Human Development Index groups
Low 8 (38) 13 (62) Ref. -
Lower middle 22 (79) 6 (21) 3.1 (0.9–11)
Upper middle 32 (97) 1 (3) 7.4 (2.3–27)
High 37 (100) 0 (0) 23 (5.7–120)
Health expenditure groups
Low 7 (28) 18 (72) Ref. -
Lower middle 22 (73) 8 (27) 7.0 (2.3–25)
Upper middle 24 (86) 4 (14) 15 (4.3–69)
High 31 (86) 5 (14) 16 (4.7–64)
Physician density groups
Low 5 (26) 14 (74) Ref. -
Lower middle 19 (68) 9 (32) 5.9 (1.7–23)
Upper middle 28 (82) 6 (18) 13 (3.6–56)
High 32 (84) 6 (16) 15 (4.2–63)
Table 3 Multivariable logistic regression producing adjusted
odds ratios (95% CI) for reporting having a surveillance system
by binary socioeconomic indicators, using lower categories as
reference groups
Crude odds
ratio (95%CI)
Adjusted odds
ratio (95%CI)
P-value
multivariable
model
(Wald’s test)
Income level 12 (3.4–46) 0.7 (0.1–9.9) 0.783
Human Development
Index
44 (5.6–340) 26 (2.0–340) 0.013
Health expenditure 15 (3.3–69) 1.7 (0.1–36) 0.727
Physician density 8.8 (2.7–28) 2.3 (0.5–9.0) 0.241
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study is that it points to the importance of addressing
these issues worldwide without regard for country socio-
economic status.
Most notably, less than half of the 119 WHO MS in-
cluded in this analysis reported having a written national
viral hepatitis strategy or plan, and less than half reported
funding viral hepatitis awareness campaigns. The 2014
World Health Assembly resolution on viral hepatitis [7]
may have encouraged some governments to give greater
attention to viral hepatitis, and it seems likely that
more countries have enacted strategies and have funded
awareness campaigns since the resolution was approved.
What is important for steering the global response to viral
hepatitis is to recognise that countries at all levels of
socioeconomic development warrant monitoring in these
regards, and that all countries might benefit from tech-
nical support in relation to developing viral hepatitis strat-
egies and raising public awareness.
In our study, the only association that remained in
multivariate analysis was an association between having
routine viral hepatitis surveillance and being in the
higher binary HDI category. As noted in the methodology
section, HDI scores reflect three measures: life expectancy
at birth, mean years over expected years of schooling, and
gross national income per capita [16]. The study finding
thus suggests that a country’s willingness or capacity to
implement routine viral hepatitis surveillance is not
merely a funding issue. It may be the case that multiple
other elements of strong health systems are required in
order for governments to consider it feasible to implement
routine viral hepatitis surveillance – for example, high-
functioning healthcare delivery systems and an educated
workforce. If this is the case, then merely providing finan-
cial support to lower-income countries to implement viral
hepatitis surveillance may be an inadequate strategy for
improving the situation, and more complex interventions
should be considered.
Contrary to expectation, our results do not show that
countries with markers of high socioeconomic status
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hepatitis policies in place in any areas other than routine
surveillance. These results imply that health outcomes are
not simple products of policy and resource availability.
Rather, the circumstances that create observed outcomes
in health are likely to be more complex and multifaceted.
For example, data from the 2016 Hep-CORE policy study
in European and Mediterranean countries is consistent
with our finding that high-SES countries do not ne-
cessarily have stronger policy responses to viral hepa-
titis. High-income Hep-CORE study countries such as
Austria, Denmark and Sweden were reported to not
have national written strategies for HBV and/or HCV,
whereas middle-income Hep-CORE countries such as
Romania, Turkey and Ukraine were reported to have
such strategies [22].
Higher prevalence of viral hepatitis in low-SES countries
[2, 3] is one possible explanation that should be considered
for the failure of higher-income to distinguish themselves
with stronger policy responses. That is, the countries with
the largest viral hepatitis epidemics may have the great-
est incentive to implement policies to effectively ad-
dress this situation. This study did not seek to identify
associations between viral hepatitis prevalence and the
enactment of policies because a lack of adequate data
from many countries has made it difficult to generate
accurate estimates of the HBV and HCV disease burden
in the past [2, 3]. The situation is improving, and future
studies of factors that affect viral hepatitis policy-
making may be able to capitalise on more reliable epi-
demiological evidence.
With the introduction of WHO’s first-ever Global Health
Sector Strategy on Viral Hepatitis, 2016–2021 in May 2016,
the viral hepatitis policy landscape has changed [3]. The
strategy is potentially a powerful tool for guiding country-
level responses to viral hepatitis, with a focus on its elimin-
ation. The four viral hepatitis policy questions that served
as dependent variables in our study all reflect major com-
ponents of the Global Health Sector Strategy. Conducting
routine surveillance, for example, is essential for countries
to acquire reliable data for decision-making. Raising public
awareness about viral hepatitis is essential for encouraging
the large numbers of undiagnosed people in many coun-
tries to come forward for HBV and HCV testing. Uneven
implementation of the relevant policies across different
countries thus threatens to limit global progress toward the
elimination of HBV and HCV. WHO has proposed a moni-
toring framework to track progress toward Global Health
Sector Strategy targets, but the framework does not include
a policy component [23]. By calling attention to policy gaps
in countries at all income levels, our study suggests that it
may be beneficial to incorporate policy indicators into the
WHO monitoring framework and to encourage policy
monitoring in all countries worldwide.Limitations
Survey responses from national viral hepatitis focal points
were not cross-checked with other sources of information
to evaluate their accuracy, and it is therefore possible that
some of the policy data utilized in this study are incorrect.
Higher response rates from MS above the median HDI
and physician density suggest the potential for selection
bias. Thus, countries without viral hepatitis programmes
are likely to be underrepresented in this study. A lack of
response from countries may be attributable to the lack of
a clearly designated national focal point. Excluding re-
spondents with missing indicators may have contributed
to systematic error. Furthermore, the small sample size
may have introduced type II error, meaning that observa-
tions of non-significant associations may in fact be false.
As this was an ecological study, it is not possible to make
inferences at the individual country level. Other socioeco-
nomic or contextual indicators may, in fact, be better pre-
dictors of the policies and programmes investigated;
indeed, they may even be confounders of the current indi-
cators investigated. In addition, socioeconomic indicators
do not measure political commitment to a cause. Coun-
tries with a perceived high burden of viral hepatitis may
be more likely than other countries to have a political
commitment to addressing viral hepatitis. Nevertheless,
countries often do not have reliable prevalence estimates
available, and are unaware of the actual disease burden
and of the importance of implementing strong disease
control measures.Conclusions
Countries with higher and lower socioeconomic status
indicators did not appear to differ greatly regarding the
existence of some key national viral hepatitis policies
and programmes. This suggests that the policy response
to viral hepatitis may not merely depend on national
income and other socioeconomic factors. With regard
to country-level efforts to reduce and eliminate viral
hepatitis, a more nuanced understanding of the multi-
faceted interactions of socioeconomic factors, health
policy, service delivery and health outcomes is needed.
Further studies of this nature would benefit from the
inclusion of all WHO MS and from the use of
additional socioeconomic indicators as well as viral
hepatitis prevalence data.
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